Display options
Cite
Ridolo E, Pellicelli I, Gritti B, et al. Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide. Patient Prefer Adherence. 2019;13:145-150doi: 10.2147/PPA.S166704.
Ridolo, E., Pellicelli, I., Gritti, B., & Incorvaia, C. (2019). Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide. Patient preference and adherence, 13145-150. https://doi.org/10.2147/PPA.S166704
Ridolo, Erminia, et al. "Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide." Patient preference and adherence vol. 13 (2019): 145-150. doi: https://doi.org/10.2147/PPA.S166704
Ridolo E, Pellicelli I, Gritti B, Incorvaia C. Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide. Patient Prefer Adherence. 2019 Jan 14;13:145-150. doi: 10.2147/PPA.S166704. eCollection 2019. PMID: 30679906; PMCID: PMC6338236.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2019 Jan 14;13:145-150. doi: 10.2147/PPA.S166704. eCollection 2019.

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide.

Patient preference and adherence

Erminia Ridolo, Irene Pellicelli, Bruna Gritti, Cristoforo Incorvaia

Affiliations

  1. Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, Parma, Italy, [email protected].
  2. Cardiac/Pulmonary Rehabilitation Unit, ASST Pini-CTO, Milan, Italy.

PMID: 30679906 PMCID: PMC6338236 DOI: 10.2147/PPA.S166704

Abstract

Dual bronchodilation with long-acting beta-2 agonists and muscarinic antagonists is recommended in patients with severe to very severe COPD. Among dual bronchodilator combinations, indacaterol/glycopyrronium combination (IGC) received evidence of higher efficacy and good safety compared with monotherapy with either drug as well as with tiotropium. In randomized controlled trials, the primary outcome is usually the change in mean FEV

Keywords: dual bronchodilation; efficacy; long-acting beta-2 agonists; long-acting muscarinic antagonists; patient’s perception; severe COPD

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work. Dr Cristoforo Incorvaia reports personal fees from Staller-genes Greer, outside the submitted work.

References

  1. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001387 - PubMed
  2. Int J Chron Obstruct Pulmon Dis. 2011;6:431-8 - PubMed
  3. Int J Chron Obstruct Pulmon Dis. 2012;7:729-41 - PubMed
  4. Ther Adv Respir Dis. 2013 Feb;7(1):25-37 - PubMed
  5. Prim Care Respir J. 2013 Jun;22(2):161-8 - PubMed
  6. BMC Pulm Med. 2013 Apr 25;13:26 - PubMed
  7. Drugs. 2013 May;73(7):741-53 - PubMed
  8. Drugs Today (Barc). 2013 Jul;49(7):437-46 - PubMed
  9. PLoS One. 2013 Aug 14;8(8):e70784 - PubMed
  10. Expert Rev Clin Pharmacol. 2013 Sep;6(5):503-17 - PubMed
  11. Int J Chron Obstruct Pulmon Dis. 2013;8:425-32 - PubMed
  12. Int J Chron Obstruct Pulmon Dis. 2013;8:501-8 - PubMed
  13. Eur Respir J. 2014 Jun;43(6):1599-609 - PubMed
  14. Lancet Respir Med. 2013 May;1(3):199-209 - PubMed
  15. Expert Rev Respir Med. 2015 Feb;9(1):23-33 - PubMed
  16. Cochrane Database Syst Rev. 2015 Jan 10;1:CD010139 - PubMed
  17. Ther Adv Respir Dis. 2015 Apr;9(2):49-55 - PubMed
  18. Expert Opin Pharmacother. 2015 May;16(7):1079-90 - PubMed
  19. Int J Chron Obstruct Pulmon Dis. 2015 Nov 16;10:2495-517 - PubMed
  20. N Engl J Med. 2016 Jun 9;374(23):2222-34 - PubMed
  21. NPJ Prim Care Respir Med. 2016 Nov 24;26:16079 - PubMed
  22. Int J Chron Obstruct Pulmon Dis. 2016 Dec 30;12:141-168 - PubMed
  23. Eur Respir J. 2017 Feb 15;49(2): - PubMed
  24. Pulm Pharmacol Ther. 2017 Aug;45:19-33 - PubMed
  25. COPD. 2017 Aug;14(4):375-381 - PubMed
  26. Curr Opin Pulm Med. 2018 Jan;24(1):18-23 - PubMed
  27. Pol Merkur Lekarski. 2017 Oct 23;43(256):158-162 - PubMed
  28. Pulm Pharmacol Ther. 2018 Apr;49:11-19 - PubMed
  29. Int J Chron Obstruct Pulmon Dis. 2017 Dec 22;13:69-77 - PubMed
  30. Int J Chron Obstruct Pulmon Dis. 2018 Feb 26;13:695-702 - PubMed
  31. Curr Med Res Opin. 2019 Feb;35(2):221-227 - PubMed
  32. Expert Opin Drug Saf. 2018 Jun;17(6):637-642 - PubMed
  33. BMC Pulm Med. 2018 Jun 14;18(1):100 - PubMed
  34. Respir Res. 2018 Jun 20;19(1):121 - PubMed
  35. Int J Chron Obstruct Pulmon Dis. 2018 Jun 15;13:1949-1963 - PubMed

Publication Types